Nippon India Pharma Fund - Direct Plan - Bonus Plan

Nippon India Pharma Fund - Direct Plan - Bonus Plan

Compare
Equity
Direct
Sector - Healthcare
NAV: ₹ 469.54 as on 12-04-2024
Fund Performance

About the Nippon India Pharma Fund - Direct Plan - Bonus Plan

Nippon India Pharma Fund - Direct Plan - Bonus Plan is an equity fund. This fund was started on 1 January, 2013. The fund is managed by Sailesh Raj Bhan, Kinjal Desai. The fund could potentially beat inflation in the long-run.

Key Parameters

  1. Nippon India Pharma Fund - Direct Plan - Bonus Plan has ₹7125 Cr worth of assets under management (AUM) as on Feb 2024 and is more than category average.
  2. The fund has an expense ratio 0.9.

Nippon India Pharma Fund - Direct Plan - Bonus Plan Overview

Expense ratio
Expense ratio
0.92%
Benchmark
Benchmark
S&P BSE Healthcare PR
AUM
AUM
₹7125 Cr
Inception Date
Inception Date
1 January, 2013
Min Lumpsum/SIP
Min Lumpsum/SIP
--/--
Exit Load
Exit Load
1%
Lock In
Lock In
No Lock-in
TurnOver
TurnOver
18.67%

Nippon India Pharma Fund - Direct Plan - Bonus Plan Distribution as on (29-Feb-24)

  • Equity 97.2%

  • Debt & Cash 2.8%

Size breakup

Large cap
41.4%
Mid cap
33.1%
Small cap
22.6%
Sector Allocation

Feb'24

Jan'24

Dec'23

Health
100%

Top Holdings of Nippon India Pharma Fund - Direct Plan - Bonus Plan as on (31-Mar-24)

  • Equity

  • Debt & Cash

Equity Holdings31
Debt Holdings1

Nippon India Pharma Fund - Direct Plan - Bonus Plan: Monthly Changes Updates

All changes are between Dec'23 and Feb'24
Fund Performance
Feb'24
Jan'24
Dec'23
Fund Returns
3.21%
6.06%
4.19%
Nifty 500
1.58%
1.71%
7.25%
  • This fund’s returns stands at 3.21% whereas the fund’s underlying benchmark Nifty 500 returns stands at 1.58% as on Feb'24
  • This fund outperformed Nifty 500 by 1.63% in Feb'24
AUM Change
Parameters
Feb'24
Jan'24
Dec'23
AUM
₹ 7.1K Cr
₹ 6.9K Cr
₹ 6.5K Cr
  • AUM of the fund stands at 7.1K Cr as of Feb'24
  • AUM increased by 240.4 Cr between Feb'24 and Jan'24
Fund Portfolio Changes

Gainers & Losers in Nippon India Pharma Fund - Direct Plan - Bonus Plan portfolio Returns for the month of Feb

Nippon India Pharma Fund - Direct Plan - Bonus Plan Fund Manager

Sailesh Raj Bhan
Sailesh Raj Bhan
Fund Manager of Nippon India Pharma Fund - Direct Plan - Bonus Plan, since 1 April 2005
Kinjal Desai
Kinjal Desai
Fund Manager of Nippon India Pharma Fund - Direct Plan - Bonus Plan, since 25 May 2018

Nippon India Pharma Fund - Direct Plan - Bonus Plan Highlights

Risk meter
pointer

Very High Risk

Investors understand that their principal will be at Very High Risk
About the fund

About the fund

This fund has delivered an average annual returns of 18.42% since inception which is less than its category average return of 20.62%
Fund Allocations

Fund Allocations

This fund has an allocation of 97.16% in Equity, 0% in Debt and 2.84% in Cash related instruments
AUM size ₹7125 Cr

AUM size ₹7125 Cr

This fund has AUM of ₹7125 Cr which is more than its category average of ₹ 1650 Cr
Expense Ratio 0.92%

Expense Ratio 0.92%

This fund has an expense ratio of 0.92% which is less than its category average expense ratio of 1.45%

Frequently Asked Questions

The current NAV of Nippon India Pharma Fund - Direct Plan - Bonus Plan is ₹469.54 as on 12-Apr-2024.
Existing (Absolute + CAGR) as on 12-Apr-2024.
Nippon India Pharma Fund - Direct Plan - Bonus Plan
Absolute Returns
CAGR Returns
1 Month Returns
0.55%
0.55%
6 Month Returns
22.58%
22.58%
1 Year Returns
52.94%
52.94%
3 Years Returns
65.45%
18.27%
5 Years Returns
191.36%
23.85%
With INDmoney, the process of investing is very simple and involves zero commission.
  • Click Buy on the fund name.
  • Input the amount you are looking to invest.
  • Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
  • Select your bank account and proceed with Payment.
0.92% as on March 2024
₹7125 Cr as on March 2024
Sun Pharmaceuticals Industries Ltd(14.91%), Lupin Ltd(8.4%), Cipla Ltd(6.51%), Apollo Hospitals Enterprise Ltd(5.79%), Dr Reddy's Laboratories Ltd(4.75%) as on March 2024
The alpha ratio for the Nippon India Pharma Fund - Direct Plan - Bonus Plan for various period is as follows:
Fund Name
Alpha 1 Year
Alpha 3 Years
Alpha 5 Years
Nippon India Pharma Fund - Direct Plan - Bonus Plan
1.65
2.21
4.22
As on March 2024
The alpha for Nippon India Pharma Fund - Direct Plan - Bonus Plan is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the Nippon India Pharma Fund - Direct Plan - Bonus Plan for various period is as follows:
Fund Name
Beta 1 Year
Beta 3 Years
Beta 5 Years
Nippon India Pharma Fund - Direct Plan - Bonus Plan
0.94
0.95
0.92
As on March 2024
The Beta for Nippon India Pharma Fund - Direct Plan - Bonus Plan is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the Nippon India Pharma Fund - Direct Plan - Bonus Plan for various period is as follows:
Fund Name
Sharpe Ratio 1 Year
Sharpe Ratio 3 Years
Sharpe Ratio 5 Years
Nippon India Pharma Fund - Direct Plan - Bonus Plan
2.95
0.96
0.99
As on March 2024
The sharpe ratio for Nippon India Pharma Fund - Direct Plan - Bonus Plan is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the Nippon India Pharma Fund - Direct Plan - Bonus Plan for various period is as follows:
Fund Name
Standard Deviation 1 Year
Standard Deviation 3 Years
Standard Deviation 5 Years
Nippon India Pharma Fund - Direct Plan - Bonus Plan
14.24
15.52
18.6
As on March 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.76 as on March 2024. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 0.83 as on March 2024. It tells the consistency of the fund in generating superior risk-adjusted performance
Sailesh Raj Bhan, Kinjal Desai are the fund managers of Nippon India Pharma Fund - Direct Plan - Bonus Plan
The Exit load of Nippon India Pharma Fund - Direct Plan - Bonus Plan is 1%